Colorectal Cancer: A Patient's Guide to Diagnosis, Biomarkers, Treatment & Resistance
A patient-first evidence guide to colon and rectal cancer — from the first abnormal test and diagnosis through staging, molecular profiling, treatment, treatment resistance, monitoring, clinical trials and survivorship.
What Is Colorectal Cancer?
Colorectal cancer (CRC) includes cancers arising in the colon and rectum. Although colon and rectal cancers are often discussed together, their management can differ depending on the tumour location, stage and clinical circumstances.
Colon Cancer
Cancer arising in the large intestine. Treatment may involve combinations of surgery, chemotherapy, targeted therapy and, for selected biomarker-defined cancers, immunotherapy.
Rectal Cancer
Cancer arising in the rectum. Treatment planning can involve surgery, radiation, chemotherapy and increasingly biomarker-informed approaches.
Metastatic CRC
When colorectal cancer has spread to distant organs, treatment becomes highly dependent on disease distribution, molecular profile, previous therapy and whether local treatment of metastases is possible.
The 7 Questions Every Colorectal Cancer Patient Should Understand
Instead of beginning with dozens of drugs and technical terms, Cancer Academy starts with the questions patients actually face.
What exactly is my cancer?
Understand whether the diagnosis is colon or rectal cancer, the pathology, tumour location, grade and other characteristics.
What stage is it?
Staging describes how extensive the cancer is and helps determine which treatment strategies may be considered.
What biomarkers does my tumour have?
Biomarker testing can identify molecular features that may influence treatment selection.
What are my treatment options?
Treatment may include surgery, chemotherapy, radiation, immunotherapy, targeted therapy or combinations depending on the situation.
What happens if treatment stops working?
Cancer can develop or already possess mechanisms of resistance. Understanding resistance helps explain why treatment strategies sometimes change.
How do we know whether treatment is working?
Doctors may use imaging, laboratory tests, tumour markers, clinical assessment and, in selected settings, molecular monitoring such as circulating tumour DNA.
What comes next?
Treatment planning is an evolving process. The next decision may involve another treatment line, surgery, surveillance, a clinical trial or supportive and survivorship care.
Your Colorectal Cancer Journey
You do not need to read everything. Enter the Academy at the point that matches your current situation.
Something Was Found
Screening, symptoms, colonoscopy, imaging or an abnormal test has raised concern.
Explore diagnosis →I Have a Diagnosis
Learn about pathology, staging and the information that usually matters next.
Understand staging →I Am Starting Treatment
Understand the major treatment categories and why different patients receive different combinations.
Explore treatment →My Cancer Came Back or Progressed
Learn how recurrence and treatment resistance are evaluated and how molecular testing can influence subsequent decisions.
Explore resistance →Step 1: Diagnosis — What Do I Actually Have?
A colorectal cancer diagnosis is more than a single word on a pathology report. The clinical team typically integrates pathology, tumour location, imaging, stage and molecular information.
Pathology
- Histologic type
- Grade and differentiation
- Depth of tumour invasion
- Lymph-node involvement
- Surgical margins when applicable
Clinical Information
- Tumour location
- Imaging findings
- Distant metastases
- Symptoms and performance status
- Previous cancer treatment
Step 2: Understand the Stage
Staging helps describe how far colorectal cancer has progressed. It is one of the major foundations of treatment planning, but it is not the only one.
Stage I
Cancer is generally confined to the bowel wall without regional lymph-node involvement.
Stage II
Cancer has grown more deeply through the bowel wall but has not spread to regional lymph nodes.
Stage III
Regional lymph nodes are involved but distant metastasis has not been identified.
Stage IV
Distant metastasis is present. Importantly, stage IV disease is biologically and clinically heterogeneous.
Step 3: The Colorectal Cancer Biomarker Map
Modern colorectal cancer care increasingly combines anatomical staging with molecular information. NCI notes that biomarker testing is routinely used in colorectal cancer and can help determine treatment options. :contentReference[oaicite:1]{index=1}
Step 4: Understanding Colorectal Cancer Treatment
There is no single colorectal cancer treatment. Treatment is selected according to the clinical and molecular characteristics of the disease.
Surgery
Surgery can be central to treatment for localized colorectal cancer and may also have a role in selected metastatic disease.
Chemotherapy
Fluoropyrimidines, oxaliplatin and irinotecan-based regimens remain important components of colorectal cancer treatment.
Radiation
Radiation has an important role in selected rectal cancers and may also be used in particular metastatic or symptom-control settings.
Targeted Therapy
Molecular alterations such as BRAF V600E, HER2 amplification and selected RAS alterations can create opportunities for targeted treatment.
Immunotherapy
Immune checkpoint therapy is particularly important for selected biomarker-defined colorectal cancers, including dMMR/MSI-H disease.
Clinical Trials
Clinical trials can provide access to emerging strategies and are an important part of the colorectal cancer research ecosystem.
Colorectal Cancer & Immunotherapy
One of the clearest examples of biomarker-driven oncology is the relationship between mismatch-repair deficiency / microsatellite instability and immune checkpoint therapy.
NCI describes MSI-H status as predictive of response to checkpoint inhibition and lists checkpoint inhibitors including pembrolizumab, nivolumab and ipilimumab among immunotherapy approaches used in appropriate colon cancer settings. :contentReference[oaicite:2]{index=2}
For patients with mismatch-repair-proficient or microsatellite-stable disease, the biology is different and immunotherapy generally requires a different evidence context. Clinical trials continue to investigate ways to make otherwise immunotherapy-resistant colorectal cancers more responsive.
See the broader OneDayMD resources on oncology and systems-based cancer treatment and the Cancer Academy's broader treatment-resistance section .
Colorectal Cancer Targeted Therapy
Targeted therapy is one reason molecular testing has become increasingly important in advanced colorectal cancer.
BRAF V600E
BRAF V600E is a clinically important colorectal cancer alteration. BRAF-directed therapy is generally used in combination strategies rather than BRAF inhibition alone.
RAS
KRAS and NRAS alterations can influence whether EGFR-directed antibodies are appropriate.
HER2
HER2-positive colorectal cancer represents a smaller molecular subgroup for which HER2-directed strategies are being used and studied.
KRAS G12C
KRAS G12C is an example of increasingly specific molecular targeting in colorectal cancer, with combination approaches being studied and used in appropriate settings.
NTRK
Rare NTRK fusions can provide an actionable target across tumour types.
Next-Generation Sequencing
Comprehensive tumour profiling can identify multiple potentially relevant alterations rather than testing one biomarker at a time.
NCI identifies KRAS, BRAF, MSI/MMR and other molecular findings as clinically relevant colorectal cancer biomarkers, while current research continues to expand the number of potentially targetable alterations. :contentReference[oaicite:3]{index=3}
Step 5: Why Colorectal Cancer Can Stop Responding
Cancer treatment resistance is not necessarily evidence that a previous treatment was "wrong." Tumours can contain multiple subclones, and treatment can change the evolutionary composition of the disease.
Primary Resistance
The tumour does not respond meaningfully to a treatment from the beginning.
Acquired Resistance
The cancer initially responds but later develops or selects mechanisms that allow it to grow despite treatment.
Pathway Reactivation
Molecular signalling pathways can reactivate downstream or through alternative mechanisms.
Tumour Heterogeneity
Different cancer cells within the same patient can have different biological characteristics.
Microenvironment
Immune cells, stromal cells, blood vessels and other components surrounding the tumour can influence treatment response.
Drug Exposure
Pharmacology, tumour penetration and drug-efflux mechanisms can influence how much active treatment reaches cancer cells.
Step 6: How Is Colorectal Cancer Monitored?
Imaging
CT, MRI, PET or other imaging may be used depending on the clinical situation.
CEA
Carcinoembryonic antigen may be useful for monitoring some patients, but it is not a perfect test and must be interpreted in context.
Clinical Assessment
Symptoms, physical findings, functional status and treatment toxicity remain important.
ctDNA
Circulating tumour DNA is an active research area for minimal residual disease and treatment monitoring.
Metastatic Colorectal Cancer: Think in Systems
Metastatic colorectal cancer should not be viewed simply as "stage IV." A more useful framework considers several dimensions simultaneously.
Where?
Liver, lung, peritoneum, distant lymph nodes or other locations.
How Much?
Number, size and distribution of metastatic lesions.
How Fast?
Disease behaviour over time and response to previous treatments.
What Biology?
RAS, BRAF, MSI/MMR, HER2 and other potentially relevant biomarkers.
What Has Been Tried?
Previous chemotherapy, targeted therapy, immunotherapy and local treatments.
What Is Possible Locally?
Selected patients may be considered for surgery, ablation, radiation or other local approaches.
Clinical Trials: The Future of Colorectal Cancer Treatment
Colorectal cancer research is moving rapidly across immunotherapy, targeted therapy, molecular monitoring, circulating tumour DNA, novel combinations and biomarker-defined treatment.
NCI currently lists active colorectal cancer trials involving biomarker-directed treatment, ctDNA and novel targeted strategies. :contentReference[oaicite:5]{index=5}
How Cancer Academy Grades Evidence
Cancer Academy uses an evidence hierarchy designed to prevent promising laboratory findings from being presented as established patient treatments.
The 10 Cancer Academy Schools Behind This Guide
Colorectal cancer is not isolated from the wider oncology knowledge system. The disease-specific school connects to ten broader Cancer Academy knowledge domains.
1. Cancer Biology
How colorectal cancer develops, evolves and spreads.
2. Diagnosis & Staging
Pathology, imaging and clinical classification.
3. Biomarkers
MMR/MSI, RAS, BRAF, HER2 and other molecular features.
4. Surgery & Local Therapy
Resection, metastasectomy, ablation and radiation concepts.
5. Systemic Therapy
Chemotherapy, immunotherapy and targeted therapy.
6. Treatment Resistance
Why cancers stop responding and how resistance is studied.
7. Metabolic & Lifestyle Health
Nutrition, physical activity, metabolic health and supportive care evidence.
8. Precision Oncology
Molecular profiling and treatment matching.
9. Clinical Trials
Emerging treatments and experimental strategies.
10. Survivorship
Follow-up, recurrence surveillance, quality of life and long-term health.
Coming to the Cancer Academy: Patient Tools
CRC Biomarker Interpreter
Enter a patient's reported biomarker results and receive an educational explanation of what each term means.
Treatment Question Builder
Generate a personalized list of questions to discuss with an oncology team.
Clinical Trial Navigator
Explore clinical-trial concepts by cancer type, biomarker, treatment history and disease stage.
Resistance Mapper
Educational visualization of major mechanisms of treatment resistance.
Evidence Checker
Distinguish laboratory, observational, clinical-trial and established evidence.
Patient Report Organizer
Organize pathology, imaging, biomarker and treatment information for discussion with healthcare professionals.
Continue Learning Across OneDayMD
Colorectal cancer intersects with several broader OneDayMD oncology pillars.
Systems Oncology
Explore cancer as an interconnected system involving genetics, metabolism, immunity and the tumour microenvironment.
Explore the oncology framework →Immunotherapy
Learn how checkpoint inhibitors, tumour biomarkers and immune resistance fit together.
Explore immunotherapy resources →Cancer Treatment Resistance
Understand primary resistance, acquired resistance and evolutionary mechanisms of treatment failure.
Explore resistance research →Cancer Prevention
Explore evidence-based approaches to reducing modifiable cancer risk.
Explore prevention →Internal links are designed to connect the colorectal cancer school with the broader OneDayMD Cancer Academy knowledge graph. Individual destination URLs should be audited periodically as the OneDayMD network evolves.
Questions to Take to Your Oncology Appointment
- What is the exact pathology diagnosis?
- Where is the primary tumour located?
- What is my TNM stage?
- Has the tumour been tested for MMR/MSI?
- What are my KRAS and NRAS results?
- Has BRAF V600E been tested?
- Has HER2 been evaluated where appropriate?
- Would broader molecular profiling be useful?
- What is the goal of treatment?
- What are the expected benefits and major risks?
- How will we know whether treatment is working?
- What would we consider if the cancer progresses?
- Are there relevant clinical trials?
- Would a second pathology or oncology opinion be useful?
Frequently Asked Questions
Is colorectal cancer the same as colon cancer?
No. Colorectal cancer is the broader term covering cancers of the colon and rectum. Colon and rectal cancers can require different treatment strategies depending on their location and stage.
Why are biomarkers important in colorectal cancer?
Biomarkers can provide information about tumour biology and may influence treatment selection. Important colorectal cancer biomarkers include MMR/MSI, RAS, BRAF and HER2, among others.
Does MSI-H mean immunotherapy will work?
MSI-H/dMMR status is an important predictor of response to immune checkpoint therapy, but an individual treatment decision still depends on the complete clinical context.
What happens if colorectal cancer becomes resistant to treatment?
The oncology team may reassess imaging, pathology, molecular characteristics and previous treatments. Depending on the situation, another treatment line, local therapy, biomarker-directed therapy or a clinical trial may be considered.
Is ctDNA ready to replace conventional monitoring?
No. ctDNA is an important and rapidly developing research and clinical technology, but evidence is still evolving regarding how best to use it to guide treatment decisions in different colorectal cancer settings.
Can stage IV colorectal cancer ever be treated with surgery?
Selected patients with metastatic disease may be considered for surgery or other local treatments of metastatic sites. Whether this is appropriate depends on factors such as the location, number and resectability of metastases and the overall disease biology.
Does Cancer Academy recommend cancer treatments?
Cancer Academy is an educational platform. It explains evidence, treatment concepts, biomarkers, clinical trials and areas of uncertainty. It does not replace individualized medical advice or prescribe treatment.
How OneDayMD Cancer Academy Approaches Cancer Information
Evidence First
Claims are classified according to the strength and type of available evidence.
Patient First
Technical oncology concepts are translated into questions and decisions patients can understand.
No Miracle Claims
Experimental findings are not presented as established treatments.
Uncertainty Is Explicit
Areas where evidence remains incomplete or conflicting are identified rather than hidden.
Sources Matter
Major claims should be traceable to high-quality clinical guidelines, regulatory sources, peer-reviewed research and authoritative cancer organizations.
Educational, Not Prescriptive
Cancer Academy supports informed conversations with healthcare professionals rather than replacing them.
Your Cancer. Your Questions. Better Information.
Colorectal cancer is no longer understood only by stage. Modern oncology increasingly combines anatomy, pathology, molecular biology, treatment response and disease evolution.
The Cancer Academy's purpose is to make that complexity understandable — without turning uncertainty into false certainty.
Selected Evidence Sources
-
National Cancer Institute — Biomarker Testing for Cancer Treatment
cancer.gov -
National Cancer Institute — Colon Cancer Treatment
cancer.gov -
National Cancer Institute — Advances in Colorectal Cancer Research
cancer.gov -
National Cancer Institute — Colorectal Cancer Clinical Trials
cancer.gov
Evidence and treatment recommendations evolve. Always check current clinical guidelines and discuss individual circumstances with a qualified oncology team.
.png)
.png)
Comments
Post a Comment